Anupkumar George

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 249 citations · Full text

Hematological Malignancy, Oncology, Hematology +6

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol et al. · The Lancet Haematology · 2019 · 237 citations · Full text

Hematological Malignancy, Medicine, Immunology +7

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

Chan Y. Cheah, Anupkumar George, Eva Giné et al. · Annals of Oncology · 2013 · 130 citations · Full text

Prognostic Factors, Neuro-oncology, Lymphoid Neoplasia +4

A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · Journal of Clinical Oncology · 2018 · 26 citations

Immunology, Pharmacotherapy, Infusion Reaction +17

High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma

Raghava Kashyap, Eddie Lau, Anupkumar George et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2013 · 23 citations · Full text

Positron Emission Tomography, Health Sciences, Focal Fat Necrosis +5